期刊
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
卷 36, 期 8, 页码 3197-3201出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.jvca.2022.02.026
关键词
right ventricular assist device; extracorporeal membranous oxygenation; COVID-19; ProtekDuo; acute respiratory distress syndrome
The importance of the right ventricle (RV) has been magnified due to the exacerbation of RV failure caused by severe acute respiratory syndrome coronavirus 2 infection. Venovenous extracorporeal membranous oxygenation (VV-ECMO) has become a main treatment for severe COVID-19 acute respiratory distress syndrome, and early implementation of a right ventricular assist device may improve patient outcomes.
Often labeled the forgotten ventricle, the right ventricle's (RV) importance has been magnified over the last 2 years as providers witnessed how severe acute respiratory syndrome coronavirus 2 infection has a predilection for exacerbating RV failure. Venovenous extracorporeal membranous oxygenation (VV-ECMO) has become a mainstay treatment modality for a select patient population suffering from severe COVID-19 acute respiratory distress syndrome. Concomitant early implementation of a right ventricular assist device with ECMO (RVAD-ECMO) may confer benefit in patient outcomes. The underlying mechanism of RV failure in COVID-19 has a multifactorial etiopathogenesis; nonetheless, clinical evaluation of a patient necessitating RV support remains unchanged. Herein, the authors report the case of a critically ill patient who was transitioned from a conventional VV-ECMO Medtronic Crescent cannula to RVAD-ECMO, with the insertion of the LivaNova ProtekDuo dual-lumen RVAD cannula. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据